A detailed history of Rhumbline Advisers transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 100,872 shares of EWTX stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100,872
Previous 98,269 2.65%
Holding current value
$3.25 Million
Previous $1.77 Million 52.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.88 - $29.5 $41,335 - $76,788
2,603 Added 2.65%
100,872 $2.69 Million
Q2 2024

Aug 01, 2024

BUY
$15.08 - $21.23 $211,738 - $298,090
14,041 Added 16.67%
98,269 $1.77 Million
Q1 2024

May 09, 2024

BUY
$9.25 - $19.97 $184,028 - $397,303
19,895 Added 30.93%
84,228 $1.54 Million
Q4 2023

Feb 08, 2024

BUY
$5.51 - $12.1 $3,983 - $8,748
723 Added 1.14%
64,333 $703,000
Q3 2023

Nov 09, 2023

BUY
$5.73 - $7.69 $1,890 - $2,537
330 Added 0.52%
63,610 $364,000
Q2 2023

Aug 08, 2023

BUY
$5.71 - $10.29 $28,258 - $50,925
4,949 Added 8.48%
63,280 $490,000
Q1 2023

May 11, 2023

BUY
$6.66 - $11.33 $48,891 - $83,173
7,341 Added 14.4%
58,331 $389,000
Q4 2022

Feb 14, 2023

BUY
$7.58 - $11.08 $51,885 - $75,842
6,845 Added 15.51%
50,990 $456,000
Q3 2022

Nov 10, 2022

BUY
$8.08 - $13.58 $19,642 - $33,012
2,431 Added 5.83%
44,145 $434,000
Q2 2022

Aug 11, 2022

BUY
$5.67 - $9.87 $27,516 - $47,899
4,853 Added 13.17%
41,714 $332,000
Q1 2022

May 12, 2022

BUY
$9.1 - $18.97 $57,785 - $120,459
6,350 Added 20.81%
36,861 $358,000
Q4 2021

Feb 10, 2022

BUY
$14.41 - $22.41 $439,663 - $683,751
30,511 New
30,511 $466,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $2.03B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.